Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder

Stopped early · Phase 3 · Has a placebo group

Conditions studied: Overactive Bladder

In brief

This study will assess the safety and efficacy of botulinum toxin Type A for the treatment of urinary incontinence overactive bladder in patients with a spinal cord injury or multiple sclerosis.

Key facts

Study ID

NCT00439140

Run by

Allergan

People needed

41

Starts

2007-06-01

Expected to finish

2012-12-01

Last updated by the study team

2014-01-24

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Urinary incontinence as a result of neurogenic overactive bladder due to spinal cord injury or multiple sclerosis
• Inadequate response to anticholinergic medication used to treat overactive bladder.
• Neurological respiratory impairment and abnormal pulmonary function test results

You may not qualify if…

• History or evidence of pelvic or urologic abnormality
• Previous or current diagnosis of bladder or prostate cancer
• Symptomatic or untreated urinary tract infection at time of enrollment

Where it is running

• Study site — Philadelphia, Pennsylvania, United States
• Study site — Herston, Queensland, Australia
• Study site — Victoria, British Columbia, Canada
• Study site — Chennai, India

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.